Open Nav

IMV Inc.

  • Frederic Ors, IMV Inc.

Raise awareness on technology/product and clinical results

  • Date:Thursday, October 18
  • Time:9:00 AM - 9:15 AM
  • Room:Elizabethan D
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Publicly Traded Company
  • Company Description/Mission Statement:IMV is a clinical stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases. IMV is pioneering a new class of immunotherapies based on the Company’s proprietary drug delivery platform. This patented technology leverages a novel mechanism of action that enables the reprogramming of immune cells in vivo, which are aimed at generating powerful new synthetic therapeutic capabilities. IMV’s lead candidate, DPX-Survivac, is a T cell activating immunotherapy that combines the utility of the platform with a target: survivin. IMV is currently conducting three Phase 2 studies with Incyte and Merck assessing DPX-Survivac as a combination therapy in ovarian cancer and diffuse large B-cell lymphoma
  • Company Website:
  • Company HQ City:Halifax
  • Company HQ Country:Canada
  • Company HQ State:Nova Scotia
  • Market Cap:200M
  • Ticker:IMV
  • Exchange:TSX, NASDAQ
  • CEO/Top Company Official:Frederic Ors
  • Year Founded:2000
  • Main Therapeutic Focus:Oncology
  • Lead Product in Development :DPX-Survivac
  • Development Phase of Primary Product:Phase II
  • Number Of Unlicensed Products (For Which You Are Seeking Partners) :1
Frederic Ors
IMV Inc.